Publicador de contenidos


Efecto de combinaciones de fármacos y péptidos antibacterianos frente a 'M. tuberculosis' utilizando métodos in vitro y ex vivo. Análisis en fase exponencial y en latencia

01/01/2017 - 30/03/2017
Ministerio de Ciencia, Innovación y Universidades. Instituto de Salud Carlos III. Unión Europea. Este proyecto está cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER). “Una manera de hacer Europa”


  1. Determine the synergistic activity of in vitro methods and the efficacy using a human macrophage model (THP-1 cell line) of the following combinations: Levofloxacin+clofazimine+PA-824; quinolone UB-8902 +clofazimine+PA-824; moxifloxacin+clofazimine+PA-8242.
  2. Determine the MIC of a collection of 14 antimicrobial peptides against M tuberculosis.
  3. Study the activity of the peptide and drug combinations of objectives 1 and 2 against clinical strains of M tuberculosis in latency.



We will use 10 multiresistant and 10 susceptible clinical strains of M. tuberculosis. The MIC of individual drugs will be determined using solid culture medium 7H11. The efficacy of the proposed combinations will be analyzed with the chequerboard method using solid culture medium and with the killing curves method, using liquid (7H9) and solid (7H11) culture medium.

Moreover, the combinations will be analyzed in a human macrophage model (THP-1 cell line). In this model the intracellular drug concentrations will be determined. On the other part, the MIC of a collection of 14 antimicrobial peptides will be analyzed, using liquid medium 7H9 and alamar blue reading.

Lastly, the effect of drugs alone and in combination and also the antimicrobial peptides, will be studied in a latency model based on nutrient starvation using PBS as culture medium.

Total Funding

69,575.00 euros

Project Code


Nuestro equipo

Equipo ISGlobal

Otros proyectos

Ver proyectos pasados


Combatiendo la Resistencia Bacteriana en Europa


Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting


Combatting Bacterial Resistance in Europe - Carbapenem Resistance


Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women


Integrating and decentralizing diabetes and hypertension services in Africa


Improving Care through Azithromycin Research for Infants in Africa


Predicting the Future: Incipient Tuberculosis


Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19


Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV


Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status


Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring


ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)


Digital Twins Enabled Indoor Air Quality Management for Healthy Living


Community knowledge generation through scientific culture, urban ecology and art


Building Scalable Pathogen Genomic Epidemiology in Ethiopia

Hepatitis C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.


Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias